Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-12-19
2004-08-03
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C548S154000, C548S151000, C514S368000, C514S300000, C514S360000, C514S254020, C546S121000, C544S318000, C544S133000
Reexamination Certificate
active
06770642
ABSTRACT:
BACKGROUND OF THE INVENTION
Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the neurotransmitter 5-hydroxytryptamine (5-HT) or serotonin. Serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others. The effects of serotonin are regulated by the various 5-HT receptor subtypes. Known 5-HT receptors include the 5-HT1 family (e.g. 5-HT1A), the 5-HT2 family (e.g. 5-HT2A), 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes.
The recently identified human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CA1, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA are seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues. The high affinity of a number of antipsychotic agents for the 5-HT6 receptor, in addition to its mRNA localization in striatum, olfactory tubercle and nucleus accumbens suggests that some of the clinical actions of these compounds may be mediated through this receptor. Therefore, 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorder, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia or bulimia), neurodegenerative disorders (e.g. stroke or head trauma), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine or benzodiazepines), schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.
Therefore, it is an object of this invention to provide compounds which are useful as therapeutic agents in the treatment of a variety of central nervous system disorders related to or affected by the 5-HT6 receptor.
It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
It is a feature of this invention that the compounds provided may also be used to further study and elucidate the 5-HT6 receptor.
These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
SUMMARY OF THE INVENTION
The present invention provides an indolylalkylamine derivative of formula I
wherein
Q is SO
2
, CO, CONR
9
or CSNR
10
;
n is an integer of 2 or 3;
R
1
and R
2
are each independently H, halogen, CN, OCO
2
R
12
, CO
2
R
13
, CONR
14
R
15
, CNR
16
NR
17
R
18
, SO
m
R
19
, NR
20
R
21
, OR
22
, COR
23
or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
3
and R
4
are each independently H or an optionally substituted C
1
-C
6
alkyl group;
R
5
and R
6
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R
5
and R
6
may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S;
R
7
is H, halogen, or a C
1
-C
6
alkyl, C
1
-C
6
alkoxy, aryl or heteroaryl group each optionally substituted;
R
8
is an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
m is 0 or an integer of 1 or 2;
R
9
and R
10
are each independently H or a C
1
-C
6
alkyl, aryl or heteroaryl group each optionally substituted;
R
12
, R
13
, R
19
and R
23
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
14
, R
15
and R
22
are each independently H or an optionally substituted C
1
-C
6
alkyl group; and
R
16
, R
17
, R
18
, R
20
and R
21
are each independently H or an optionally substituted C
1
-C
4
alkyl group; or R
20
and R
21
may be taken together with the atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S; or
the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
The present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
DETAILED DESCRIPTION OF THE INVENTION
The 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent receptors to be identified by molecular cloning. Its ability to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. Significant efforts are being made to understand the possible role of the 5-HT6 receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic agents in the treatment of central nervous system disorders, for example see C. Reavill and D. C. Rogers, Current Opinion in Investigational Drugs, 2001, 2(1):104-109, Pharma Press Ltd.
Surprisingly, it has now been found that indolylalkylamine derivatives of formula I demonstrate 5-HT6 affinity. Advantageously, said amine derivatives may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor. Accordingly, the present invention provides indolylalkylamine derivatives of formula I
wherein
Q is SO
2
, CO, CONR
9
or CSNR
10
;
n is an integer of 2 or 3;
R
1
and R
2
are each independently H, halogen, CN, OCO
2
R
12
, CO
2
R
13
, CONR
14
R
15
, CNR
16
NR
17
R
18
, SO
m
R
19
, NR
20
R
21
, OR
22
, COR
23
or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
3
and R
4
are each independently H or an optionally substituted C
1
-C
6
alkyl group;
R
5
and R
6
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted, or R
5
and R
6
may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing an additional heteroatom selected from O, N or S;
R
7
is H, halogen, or a C
1
-C
6
alkyl, C
1
-C
6
alkoxy, aryl or heteroaryl group each optionally substituted;
R
8
is an optionally substituted 8- to 13-membered bicyclic or tricyclic ring system having a N atom at the bridgehead and optionally containing 1, 2 or 3 additional heteroatoms selected from N, O or S;
m is 0 or an integer of 1 or 2;
R
9
and R
10
are each independently H or a C
1
-C
6
alkyl, aryl or heteroaryl group each optionally substituted;
R
12
, R
13
, R
19
and R
23
are each independently H or a C
1
-C
6
alkyl, C
2
-C
6
alkenyl, C
2
-C
6
alkynyl, C
3
-C
6
cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R
14
, R
15
and R
22
are each i
Cole Derek Cecil
Lennox William Joseph
Stock Joseph Raymond
Zhou Ping
Lences Barbara L.
Liu Hong
Raymond Richard L.
Wyeth
LandOfFree
Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3348141